The IRd regimen helps patients with cytogenetic high-risk MM to achieve lasting remission, with 1q21 amplification case analysis

Professor Deer Quanyi

• Director of the Department of Hematology, Zhongshan Hospital, affiliated to Xiamen University

• Ph.
  D.
  /Postdoctoral Supervisor, School of Medicine, Xiamen University

• Xiamen technical top talents

• Vice President of Hematologist Branch of Fujian Medical Association

• Vice Chairman of the Hematology Branch of Fujian Society of Integrative Medicine

• Chairman of Fujian Lymphoma Branch of China Union for Cancer Prevention and Control (UCOM).
  

• Vice Chairman of Fujian Province of the Anti-Lymphoma Alliance of the Chinese Society of Clinical Oncology (CSCO).
  

• Member of the Chinese Geriatrics Association and member of the Myeloma Committee

• Editorial board member of Chinese Journal of Experimental Hematology

• Mainly engaged in stem cell transplantation clinical research, in the field of cord blood transplantation by stem cells, childhood thalassemia transplantation
  .
  He has presided over 2 projects of the National Natural Science Foundation of China, a number of provincial and municipal science and technology projects, won 3 Xiamen Science and Technology Achievement Awards, published more than 30 SCI research papers and 2 monographs

• One patient with MM with 1q21 high-risk factors had poor efficacy with T-VAd regimen (thalidomide + vincristine + epirubicin + dexamethasone), developed severe neurotoxicity after switching to VTd regimen (bortezomib + thalidomide + dexamethasone), developed disease progression after half a year, and then switched to IRd regimen for 8 courses and obtained complete remission (CR), and continued IRd regimen treatment for 18 courses , efficacy assessment showed persistent CR.
  
  

• Nine patients with newly-diagnosed high-risk MM with 1q21 amplification received bortezomib-based first-line induction regimen for 1-4 courses and then switched to IRd regimen, with deepening remission and a reduced
  incidence of peripheral neuropathy.
  

1q21 amplification is one of the common high-risk cytogenetic abnormalities of MM, and patients with MM with 1q21 amplification have a poor
prognosis.
The TOURMALINE-MM1 ^study1 showed that IRd regimens could deepen remission in high-risk MM patients with a low
incidence of adverse effects.
IRd regimens as an all-oral regimen improve patient adherence, provide new treatment options for MM patients with 1q21 amplification, and help improve their clinical outcomes
.

References

[1] Hervé Avet-Loiseau, et al.
Blood 2017; 130(24):2610–2618.